BAVA Stock Overview
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Bavarian Nordic A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.20.91 |
| 52 Week High | kr.29.17 |
| 52 Week Low | kr.16.97 |
| Beta | 1.33 |
| 1 Month Change | -4.61% |
| 3 Month Change | 0.97% |
| 1 Year Change | -14.37% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -26.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| BAVA | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | 4.9% | 2.8% | 0.9% |
| 1Y | -14.4% | -10.4% | 6.7% |
Return vs Industry: BAVA underperformed the Austrian Biotechs industry which returned -10.4% over the past year.
Return vs Market: BAVA underperformed the Austrian Market which returned 6.7% over the past year.
Price Volatility
| BAVA volatility | |
|---|---|
| BAVA Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in AT Market | 5.1% |
| 10% least volatile stocks in AT Market | 1.7% |
Stable Share Price: BAVA has not had significant price volatility in the past 3 months.
Volatility Over Time: BAVA's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,379 | Paul Chaplin | www.bavarian-nordic.com |
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2.
Bavarian Nordic A/S Fundamentals Summary
| BAVA fundamental statistics | |
|---|---|
| Market cap | €1.63b |
| Earnings (TTM) | €197.74m |
| Revenue (TTM) | €946.68m |
8.2x
P/E Ratio1.7x
P/S RatioIs BAVA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAVA income statement (TTM) | |
|---|---|
| Revenue | kr.7.06b |
| Cost of Revenue | kr.1.90b |
| Gross Profit | kr.5.16b |
| Other Expenses | kr.3.69b |
| Earnings | kr.1.48b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | 18.93 |
| Gross Margin | 73.07% |
| Net Profit Margin | 20.89% |
| Debt/Equity Ratio | 0.2% |
How did BAVA perform over the long term?
See historical performance and comparison